

## ACS Chemical Neuroscience Molecule Spotlight

Beginning in issue number four of *ACS Chemical Neuroscience*, we are adding a new monthly feature called “Molecule Spotlight”. This new content will feature recently approved FDA drugs for CNS indications and highlight the molecular structure, mechanism of action, therapeutic indication, and brief synopsis of the key clinical trial data. “Molecule Spotlight” features will typically be one to two printed pages. To launch “Molecule Spotlight”, we are going back and capturing the CNS-related FDA approvals in 2009, and then we will be up-to-date with new approvals in 2010. However, as there are very few FDA approvals (only 9 for CNS indications in 2009), the content for “Molecule Spotlight” will extend beyond just new FDA approvals. Future content will include late-breaking news and profiles of small molecules and biologics that provided proof-of-concept in phase II/III trials, as well as small molecule tools that afforded key target validation for novel targets/mechanisms preclinically. The goal of this new *ACS Chemical Neuroscience* feature is to keep the neuroscience community abreast of the latest advances toward novel therapeutics for CNS disorders and highlight the molecular structures of drugs, clinical candidates and proof-of-concept compounds/biologics.

The first four “Molecule Spotlight” features have been written by Dr. Corey Hopkins, a Research Professor at Vanderbilt University who is also an Associate Director of Medicinal Chemistry within the Vanderbilt Program in Drug Discovery and codirector of the Vanderbilt MLPCN Specialized Chemistry Center. Dr. Hopkins’ inaugural “Molecule Spotlight” submissions highlight four FDA approvals of new CNS therapeutics from early 2009 (Saphris, Savella, Fanapt, and Sabril). I thank Dr. Hopkins for helping to launch this important, informative, and timely new addition to *ACS Chemical Neuroscience*.

I would also like to solicit content for the “Molecule Spotlight” feature from the *ACS Chemical Neuroscience* community at large and encourage the readership to submit a topic to me (e-mail: [eic@chemneuro.acs.org](mailto:eic@chemneuro.acs.org)) for consideration as a “Molecule Spotlight” feature. Tentatively, we plan to have one per issue (12 per year), but if interest is high, we can publish multiple “Molecule Spotlight” features per issue. This is a wonderful opportunity for young scientists in industry and academia to publish, review chemical structures, and learn about new areas of neuropharmacology and clinical trials. I welcome broad participation and encourage everyone to become part of the *ACS Chemical Neuroscience* community and discover the quality, impact, and diverse neuroscience content of *ACS Chemical Neuroscience*.

In closing, one could imagine another high impact feature could be “Technology Spotlight”, focusing on emerging, cutting-edge technology, techniques, and strategies to advance neuroscience research and address historical limitations. I would also solicit ideas and comments from the *ACS Chemical Neuroscience* community on this topic (e-mail: [eic@chemneuro.acs.org](mailto:eic@chemneuro.acs.org)).

Craig W. Lindsley\*  
*Editor-in-Chief*

Published on Web Date: April 21, 2010